Trinity Biotech (TRIB) Long-Term Investments (2019 - 2025)

Trinity Biotech (TRIB) has reported Long-Term Investments for 7 consecutive years, with $2.8 million the latest figure, recorded in Q4 2025.

• Quarterly Long-Term Investments rose 12.95% year-over-year to $2.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.8 million (up 12.95% YoY) and the FY2025 annual result came in at $2.8 million, up 12.95% from the prior year.
• Long-Term Investments advanced to $2.8 million in Q4 2025 per TRIB's latest filing, from $2.5 million in the prior quarter.
• Over the last five years, Long-Term Investments for TRIB reached as high as $21.8 million in Q4 2021 and fell as low as $2.5 million in Q4 2024.
• A 5-year average of $7.6 million and a median of $4.9 million in 2023 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2022 — Long-Term Investments slumped 72.37% — and 2025, when it increased 12.95%.
• Year by year, Long-Term Investments stood at $21.8 million in 2021, then sank by 72.37% to $6.0 million in 2022, then dropped by 18.79% to $4.9 million in 2023, then plunged by 49.84% to $2.5 million in 2024, then grew by 12.95% to $2.8 million in 2025.
• According to Business Quant data, Long-Term Investments over the past three periods registered $2.8 million, $2.5 million, and $4.9 million for Q4 2025, Q4 2024, and Q4 2023 respectively.